CRISPR Therapeutics stock price slides after takeover-chatter spike
CRISPR Therapeutics shares dropped 4.7% to $58.82 in early Nasdaq trading Friday, erasing part of Thursday’s 11% surge tied to revived takeover speculation flagged by Betaville and The Fly. Investors await updates on Casgevy’s launch at early March conferences. Short interest stands near 26% of the float. Casgevy generated $54 million in Q4 revenue, with $116 million reported for 2025.